Get the latest news alerts: at Twitter.
Local Tech Wire
RESEARCH TRIANGLE PARK, N.C. – Global life sciences company is the subject of a positive review in BusinessWeek.
“From the look of things, Quintiles Transnational is having a pretty good run despite the economic turmoil of the past year and a half,” writes Nanette Byrnes.
The term simply contract research organization doesn’t encompass all that the privately held company does these days, as Byrnes points out. Through investments and partnerships, Quintiles is moving “upstream” with a much higher profile in drug development, not just clinical trials.
“To compensate for the industry slow down and continue to build on its own growth, Quintiles management is trying to move from a contract-based sub contracting role, toward partnerships with drug and biotech companies,” she points out. “In these deals, Quintiles invests money or labor, or both, into the final stages of an individual drug’s development. The payoff: a share of its long term profits.”
The article pays special attention to the NovaQuest investment group at Quintiles.
For more,
